Mallinckrodt (NYSE:MNK) – Equities researchers at SunTrust Banks issued their Q1 2018 earnings per share estimates for shares of Mallinckrodt in a research report issued on Wednesday, April 11th, Zacks Investment Research reports. SunTrust Banks analyst J. Boris forecasts that the company will earn $1.18 per share for the quarter. SunTrust Banks currently has a “Hold” rating and a $15.00 target price on the stock. SunTrust Banks also issued estimates for Mallinckrodt’s Q2 2018 earnings at $1.51 EPS, Q3 2018 earnings at $1.58 EPS, Q4 2018 earnings at $1.80 EPS, FY2018 earnings at $6.07 EPS, FY2019 earnings at $6.27 EPS, FY2020 earnings at $7.20 EPS, FY2021 earnings at $6.86 EPS and FY2022 earnings at $7.87 EPS.
Several other analysts have also issued reports on MNK. Mizuho reissued a “hold” rating and issued a $15.00 price target on shares of Mallinckrodt in a research report on Friday, April 20th. Wells Fargo set a $18.00 price target on shares of Mallinckrodt and gave the company a “hold” rating in a research report on Friday, March 16th. Leerink Swann assumed coverage on shares of Mallinckrodt in a research report on Tuesday, January 2nd. They issued a “market perform” rating and a $26.00 price target on the stock. Stifel Nicolaus lowered shares of Mallinckrodt from a “buy” rating to a “hold” rating and set a $50.00 price target on the stock. in a research report on Thursday, April 12th. Finally, Cantor Fitzgerald set a $42.00 price target on shares of Mallinckrodt and gave the company a “buy” rating in a research report on Monday, January 8th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the company. Mallinckrodt presently has an average rating of “Hold” and a consensus price target of $33.83.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.29. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The company had revenue of $792.30 million for the quarter, compared to analyst estimates of $769.91 million. During the same quarter in the previous year, the firm posted $1.91 earnings per share. The company’s quarterly revenue was down 4.5% compared to the same quarter last year.
A number of hedge funds have recently added to or reduced their stakes in MNK. State of Alaska Department of Revenue purchased a new position in Mallinckrodt in the 4th quarter worth approximately $129,000. Amundi Pioneer Asset Management Inc. purchased a new position in Mallinckrodt in the 4th quarter worth approximately $190,000. Shelton Capital Management purchased a new position in Mallinckrodt in the 3rd quarter worth approximately $205,000. Sciencast Management LP purchased a new position in Mallinckrodt in the 4th quarter worth approximately $210,000. Finally, CIBC World Markets Inc. purchased a new position in Mallinckrodt in the 4th quarter worth approximately $231,000.
TRADEMARK VIOLATION WARNING: “Mallinckrodt (NYSE:MNK) Expected to Earn Q1 2018 Earnings of $1.18 Per Share” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://stocknewstimes.com/2018/04/25/mallinckrodt-to-post-q1-2018-earnings-of-1-18-per-share-suntrust-banks-forecasts-mnk.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.